

Translation

Participation in the Global Health Innovative Technology Fund (GHIT Fund)

December 24, 2014 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Main Office: Chuo-ku, Tokyo. Chairman & CEO: Osamu Nagayama (hereafter, “Chugai”)] announced today that it has joined the Global Health Innovative Technology Fund (GHIT Fund) as Chugai agrees with the background and purposes of its establishment. The GHIT Fund has a vision of their activities: “Our vision is one in which the crushing burden of infectious disease no longer prevents billions of people in the developing world from seeking the level of prosperity and longevity now common in the industrialized world.”

Chugai’s mission is “to dedicate itself to adding exceptional value through the creation of innovative medical products and services for the benefit of the medical community and human health around the world.” It has been working on contribution to global health as a member of Roche Group. Participation in the GHIT Fund this time is also the part of Chugai’s efforts.

This year, the epidemic of Ebola hemorrhagic fever in West Africa has spread at unprecedented levels. In Japan, dengue virus infection was identified and many infected individuals were reported. Such a crisis of infections has been globally increasing. In reaction to this situation, the acceleration of research and development of drugs and vaccines, creation of innovation leading to revolutionary therapies, and international cooperation in healthcare field are becoming urgent issues.

Under these circumstances, Chugai is sure that participation in the GHIT Fund leads to searching the possibility to utilize its innovative drug development technologies for infectious diseases including “neglected tropical diseases (NTDs),” which primarily developing countries face, and thus to contribute to global healthcare.

Chugai’s business philosophy is “innovation all for the patients.” It will proactively works on activities for improving access to drugs in developing countries through the GHIT Fund and dedicate itself to promoting the health of patients and their families worldwide including these countries.

[Global Health Innovative Technology Fund (GHIT Fund)]

The Global Health Innovative Technology Fund (GHIT Fund) is an international non-for-profit organization initiated in Japan to promote the development of new drugs with the aim of taking control of infectious diseases spreading particularly in developing countries such as AIDS, tuberculosis, malaria and neglected tropical diseases (NTDs).” The GHIT Fund was established as Japan’s first public-private partnership by the Japanese Government, pharmaceutical industries and the Bill & Melinda Gates Foundation. It promotes cooperation between Japanese and overseas research organizations and the development of new drugs through providing grants.

Detailed information on the GHIT Fund is available on the Internet at www.ghitfund.org.

[Neglected Tropical Diseases (NTDs)]

Neglected Tropical Diseases (NTDs) are parasitic, bacterial and viral infections spread mainly in tropical areas. It has been reported that approximately one billion individuals are infected with NTDs and half a million people die each year worldwide. NTDs are quite rare in advanced countries so that they did not catch world’s attention. Many NTDs are parasitic diseases and may cause severe physical impairment such as deformity and blindness. Nonetheless, they can be often prevented or treated.